The article presents the review of a safety of TNF blockers in treatment of rheumatologic diseases in adults and children. Authors give a data on separate, open-labeled, and multicenter double-blinded placebo-controlled studies of tolerance to infliximab, etanercept and adalimumab. The results of studies show high effectiveness and good safety of TNF blockers in adult’s and children’s rheumatologic practice.
Key words: children, rheumatoid arthritis, juvenile arthritis, TNF blockers, treatment, safety, infliximab, adalimumab, etanercept.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2010;9(1):82-94)